Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Identification of pharmacodynamic biomarkers and common molecular mechanisms of response to genotoxic agents in cancer cell lines.

Min DJ, Zhao Y, Monks A, Palmisano A, Hose C, Teicher BA, Doroshow JH, Simon RM.

Cancer Chemother Pharmacol. 2019 Oct;84(4):771-780. doi: 10.1007/s00280-019-03898-z. Epub 2019 Jul 31.

PMID:
31367787
2.

The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel.

Monks A, Zhao Y, Hose C, Hamed H, Krushkal J, Fang J, Sonkin D, Palmisano A, Polley EC, Fogli LK, Konaté MM, Miller SB, Simpson MA, Voth AR, Li MC, Harris E, Wu X, Connelly JW, Rapisarda A, Teicher BA, Simon R, Doroshow JH.

Cancer Res. 2018 Dec 15;78(24):6807-6817. doi: 10.1158/0008-5472.CAN-18-0989. Epub 2018 Oct 24.

PMID:
30355619
3.

Longitudinal Transcriptional Response of Glycosylation-Related Genes, Regulators, and Targets in Cancer Cell Lines Treated With 11 Antitumor Agents.

Krushkal J, Zhao Y, Hose C, Monks A, Doroshow JH, Simon R.

Cancer Inform. 2017 Dec 15;16:1176935117747259. doi: 10.1177/1176935117747259. eCollection 2017.

4.
5.

Antitumour benzothiazoles. Part 32: DNA adducts and double strand breaks correlate with activity; synthesis of 5F203 hydrogels for local delivery.

Stone EL, Citossi F, Singh R, Kaur B, Gaskell M, Farmer PB, Monks A, Hose C, Stevens MF, Leong CO, Stocks M, Kellam B, Marlow M, Bradshaw TD.

Bioorg Med Chem. 2015 Nov 1;23(21):6891-9. doi: 10.1016/j.bmc.2015.09.052. Epub 2015 Oct 3.

PMID:
26474663
6.

Cediranib for metastatic alveolar soft part sarcoma.

Kummar S, Allen D, Monks A, Polley EC, Hose CD, Ivy SP, Turkbey IB, Lawrence S, Kinders RJ, Choyke P, Simon R, Steinberg SM, Doroshow JH, Helman L.

J Clin Oncol. 2013 Jun 20;31(18):2296-302. doi: 10.1200/JCO.2012.47.4288. Epub 2013 Apr 29.

7.

Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma.

Saini V, Hose CD, Monks A, Nagashima K, Han B, Newton DL, Millione A, Shah J, Hollingshead MG, Hite KM, Burkett MW, Delosh RM, Silvers TE, Scudiero DA, Shoemaker RH.

PLoS One. 2012;7(8):e41401. doi: 10.1371/journal.pone.0041401. Epub 2012 Aug 3. Erratum in: PLoS One. 2012;7(11). doi:10.1371/annotation/8c74aaee-897d-4682-b62d-d95a3506c210.

8.

Development of antiproliferative phenylmaleimides that activate the unfolded protein response.

Muus U, Hose C, Yao W, Kosakowska-Cholody T, Farnsworth D, Dyba M, Lountos GT, Waugh DS, Monks A, Burke TR Jr, Michejda CJ.

Bioorg Med Chem. 2010 Jun 15;18(12):4535-41. doi: 10.1016/j.bmc.2010.04.057. Epub 2010 Apr 24.

9.

Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts.

Monks A, Hose CD, Pezzoli P, Kondapaka S, Vansant G, Petersen KD, Sehested M, Monforte J, Shoemaker RH.

Anticancer Drugs. 2009 Sep;20(8):682-92. doi: 10.1097/CAD.0b013e32832e14e1.

PMID:
19606018
10.

Drug-induced expression of nonsteroidal anti-inflammatory drug-activated gene/macrophage inhibitory cytokine-1/prostate-derived factor, a putative tumor suppressor, inhibits tumor growth.

Martinez JM, Sali T, Okazaki R, Anna C, Hollingshead M, Hose C, Monks A, Walker NJ, Baek SJ, Eling TE.

J Pharmacol Exp Ther. 2006 Aug;318(2):899-906. Epub 2006 May 19.

PMID:
16714403
12.

The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF-kappaB activity in drug-sensitive MCF-7 cells.

Brantley E, Patel V, Stinson SF, Trapani V, Hose CD, Ciolino HP, Yeh GC, Gutkind JS, Sausville EA, Loaiza-Pérez AI.

Anticancer Drugs. 2005 Feb;16(2):137-43.

PMID:
15655410
13.

The experimental antitumor agents Phortress and doxorubicin are equiactive against human-derived breast carcinoma xenograft models.

Fichtner I, Monks A, Hose C, Stevens MF, Bradshaw TD.

Breast Cancer Res Treat. 2004 Sep;87(1):97-107.

PMID:
15377855
14.

Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells.

Brantley E, Trapani V, Alley MC, Hose CD, Bradshaw TD, Stevens MF, Sausville EA, Stinson SF.

Drug Metab Dispos. 2004 Dec;32(12):1392-401. Epub 2004 Sep 8.

PMID:
15355884
15.

Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells.

Loaiza-Pérez AI, Kenney S, Boswell J, Hollingshead M, Alley MC, Hose C, Ciolino HP, Yeh GC, Trepel JB, Vistica DT, Sausville EA.

Mol Cancer Ther. 2004 Jun;3(6):715-25.

16.

Sensitivity of renal cell carcinoma to aminoflavone: role of CYP1A1.

Loaiza-Pérez AI, Kenney S, Boswell J, Hollingshead M, Hose C, Linehan WM, Worrell R, Rubinstein L, Sausville EA, Vistica DT.

J Urol. 2004 Apr;171(4):1688-97.

PMID:
15017268
19.

DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells.

Trapani V, Patel V, Leong CO, Ciolino HP, Yeh GC, Hose C, Trepel JB, Stevens MF, Sausville EA, Loaiza-Pérez AI.

Br J Cancer. 2003 Feb 24;88(4):599-605.

20.

Increased expression of beta 2-microglobulin in multidrug-resistant tumour cells.

Scheffer GL, de Jong MC, Monks A, Flens MJ, Hose CD, Izquierdo MA, Shoemaker RH, Scheper RJ.

Br J Cancer. 2002 Jun 17;86(12):1943-50.

21.

Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumor agent 2-(4-amino-3-methylphenyl) benzothiazole.

Loaiza-Pérez AI, Trapani V, Hose C, Singh SS, Trepel JB, Stevens MF, Bradshaw TD, Sausville EA.

Mol Pharmacol. 2002 Jan;61(1):13-9.

PMID:
11752201
22.

UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines.

Monks A, Harris ED, Vaigro-Wolff A, Hose CD, Connelly JW, Sausville EA.

Invest New Drugs. 2000 May;18(2):95-107.

PMID:
10857990
23.

The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.

Webb CP, Hose CD, Koochekpour S, Jeffers M, Oskarsson M, Sausville E, Monks A, Vande Woude GF.

Cancer Res. 2000 Jan 15;60(2):342-9.

24.

Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells.

Sharom FJ, Yu X, Lu P, Liu R, Chu JW, Szabó K, Müller M, Hose CD, Monks A, Váradi A, Seprôdi J, Sarkadi B.

Biochem Pharmacol. 1999 Aug 15;58(4):571-86.

PMID:
10413294
25.

Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration.

Zhan Z, Scala S, Monks A, Hose C, Bates S, Fojo T.

Cancer Chemother Pharmacol. 1997;40(3):245-50.

PMID:
9219509
26.

Clinical Reversal of Multidrug Resistance.

Bates SE, Wilson WH, Fojo AT, Alvarez M, Zhan Z, Regis J, Robey R, Hose C, Monks A, Kang YK, Chabner B.

Oncologist. 1996;1(4):269-275.

27.

Clinical reversal of multidrug resistance.

Bates SE, Wilson WH, Fojo AT, Alvarez M, Zhan Z, Regis J, Robey R, Hose C, Monks A, Kang YK, Chabner B.

Stem Cells. 1996 Jan;14(1):56-63. Review.

28.

Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen.

Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, Grever M, Bates S, Fojo T.

J Clin Invest. 1995 May;95(5):2205-14.

29.

Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.

Lee JS, Paull K, Alvarez M, Hose C, Monks A, Grever M, Fojo AT, Bates SE.

Mol Pharmacol. 1994 Oct;46(4):627-38.

PMID:
7969041
30.

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, et al.

J Natl Cancer Inst. 1991 Jun 5;83(11):757-66.

PMID:
2041050

Supplemental Content

Support Center